FATE Stock Price
Fate Therapeutics, Inc.
FATE stock price is $1.97 (+1.29% on the day), giving Fate Therapeutics, Inc. a market cap of $232.45M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
FATE Stock Overview
- Price
- $1.97
- Previous close
- $1.94
- Open
- $1.96
- Market cap
- $232.45M
- P/E ratio
- -1.7
- 52-week range
- $0.95 - $3.23
- 1-year price target
- $5.74
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSD
- MarketXLS Rank
- 40
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FATE | $1.97 | +1.3% | 240.05K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |